Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 7/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22663739 | 0.90 | CNR1 (0.49) | CNR1DPP9CNR2DPP4DPP8 | |
| SCHEMBL24182153 | 0.86 | CNR1 (0.42) | CNR1DPP9HTR3ADPP4DPP8 | |
| SCHEMBL24182186 | 0.86 | DPP9 (0.43) | CNR1DPP9HTR3ADPP4DPP8 | |
| SCHEMBL22450746 | 0.84 | CNR1 (0.41) | CNR1DPP9DPP4DPP8DPP7 | |
| SCHEMBL22450928 | 0.83 | CNR1 (0.56) | CNR1HTR3ACNR2 | |
| SCHEMBL24182198 | 0.83 | TNF (0.53) | CNR1HTR3A | |
| SCHEMBL22450736 | 0.83 | TNF (0.53) | CNR1HTR3A | |
| SCHEMBL22450711 | 0.83 | TNF (0.53) | CNR1HTR3A | |
| SCHEMBL22450855 | 0.82 | CNR1 (0.46) | CNR1HTR3ACNR2 | |
| SCHEMBL24488639 | 0.82 | CNR1 (0.41) | CNR1DPP9HTR3ACNR2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | CNR1 4859/4885DPP9 687/4885HTR3A 4288/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | CNR1 4859/4885DPP9 687/4885HTR3A 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.